| Market Cap | 877.6Cr 764.65Cr 704.88Cr 663.01Cr 1.24TCr 83TCr 1.25TCr 8.39TCr 3.26TCr 41TCr 3.29TCr 3.22TCr 1,41300Cr | P/E 2026 * |
156x | P/E 2027 * | 33.9x |
|---|---|---|---|---|---|
| Enterprise Value | 856.26Cr 746.06Cr 687.74Cr 646.89Cr 1.21TCr 81TCr 1.22TCr 8.18TCr 3.18TCr 40TCr 3.21TCr 3.15TCr 1,37800Cr | EV / Sales 2026 * |
8.51x | EV / Sales 2027 * | 5.93x |
| Free-Float |
65.96% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corcept Therapeutics
| 1 day | +0.16% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 01/01/1999 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 01/03/2021 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 01/01/1999 |
James Wilson
CHM | Chairman | 82 | 01/01/1999 |
David Mahoney
BRD | Director/Board Member | 71 | 01/07/2004 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +13.02% | - | - | 877.6Cr | |
| -1.57% | -6.12% | +38.84% | +141.16% | 99TCr | |
| -2.74% | -4.45% | +51.08% | +38.74% | 56TCr | |
| -2.27% | -3.94% | +16.40% | +56.66% | 39TCr | |
| -2.90% | +0.68% | +24.66% | +16.53% | 33TCr | |
| -2.36% | -3.12% | +24.71% | +12.95% | 28TCr | |
| -2.45% | -2.88% | +24.29% | +29.93% | 28TCr | |
| -1.91% | -0.87% | -41.95% | -48.26% | 20TCr | |
| -1.69% | -5.21% | +15.88% | +46.83% | 18TCr | |
| -2.30% | -2.46% | +13.68% | +58.00% | 16TCr | |
| Average | -2.09% | +0.41% | +18.62% | +39.17% | 37.46TCr | |
| Weighted average by Cap. | -2.26% | -0.49% | +27.40% | +62.17% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 100.61Cr 88Cr 81Cr 76Cr 142.2Cr 9.48TCr 143.2Cr 961.4Cr 373.37Cr 4.67TCr 377.63Cr 369.54Cr 16TCr | 140.01Cr 121.99Cr 112.46Cr 105.78Cr 197.89Cr 13TCr 199.28Cr 1.34TCr 519.6Cr 6.5TCr 525.54Cr 514.28Cr 23TCr |
| Net income | 8.57Cr 7.47Cr 6.89Cr 6.48Cr 12Cr 807.95Cr 12Cr 82Cr 32Cr 398.17Cr 32Cr 31Cr 1.38TCr | 37Cr 32Cr 30Cr 28Cr 52Cr 3.47TCr 52Cr 352.19Cr 136.78Cr 1.71TCr 138.34Cr 135.38Cr 5.93TCr |
| Net Debt | -21Cr -19Cr -17Cr -16Cr -30Cr -2.01TCr -30Cr -203.91Cr -79Cr -991.07Cr -80Cr -78Cr -3.44TCr | -47Cr -41Cr -38Cr -36Cr -67Cr -4.47TCr -67Cr -453.14Cr -175.98Cr -2.2TCr -177.99Cr -174.18Cr -7.63TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
